Using methotrexate to treat arthritis caused by chikungunya virus
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection
['FUNDING_U01'] · GEORGE WASHINGTON UNIVERSITY · NIH-11190081
This study is looking at how well methotrexate works for people with chronic arthritis that can happen after chikungunya virus infection, and it will help find better treatment options for this condition.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11190081 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of methotrexate, a medication commonly used for autoimmune diseases, in treating chronic arthritis that develops after chikungunya virus infection. The study will involve a randomized controlled trial where participants will receive either methotrexate or a placebo for six months. Researchers will assess the treatment's impact on arthritis severity and inflammation by analyzing synovial tissue samples. The goal is to provide evidence-based recommendations for treating this condition, which currently lacks standard treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have developed chronic arthritis following chikungunya virus infection.
Not a fit: Patients who do not have a history of chikungunya virus infection or those with other forms of arthritis unrelated to chikungunya may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from chronic arthritis due to chikungunya virus.
How similar studies have performed: While methotrexate is commonly used for other types of arthritis, this specific application for chikungunya-related arthritis is novel and has not been extensively tested in randomized trials.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANG, AILEEN — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: CHANG, AILEEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.